Our work developed a comprehensive blueprint for the underlying mechanism through which GSDME accelerates the malignant progression of hepatocellular carcinoma and provided novel insights into the development of therapeutic targets as well as potential biomarkers for patients with LIHC. This evidence concerns the gene GSDME and hepatocellular carcinoma.